Nivolumab in NSCLC: latest evidence and clinical potential

Ther Adv Med Oncol. 2015 Mar;7(2):85-96. doi: 10.1177/1758834014567470.


New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

Keywords: immune checkpoint modulator; nivolumab; non-small cell lung cancer; programmed death-1; programmed death-1 ligand.

Publication types

  • Review